Importantly, we have also identified a novel site (site-B) that binds classical benzodiazepine agonists with low affinity (micromolar) but displays high affinity for Ro5-4884 (KD = 41 nM). Site-B displays characteristics expected for a functional receptor, including stereospecificity and sensitivity to inactivation by heat and protease treatment. Saturation binding studies employing 3H-Ro5-4884 indicate that the levels of site-B are similar in 7 and 20 d brain (ca. 2.5 pmol/mg protein). The function of site-B is not known, but its preponderance in 7 d brain, relative to site-A, suggests that it might be important during early embryonic development. Dramatic changes in the number and distribution of neurotransmitter receptors and in the kinetics of neurotransmitter biosynthesis and degradation occur during embryonic development (Wilson et al., 1970; Burden, 1977; Cochard et al., 1978; Schuetze et al., 1978) . Most developmental studies have examined classical neurotransmitter receptors such as ACh and GABA (Enna et al., 1976) , which directly elicit a postsynaptic response. Benzodiazepines (BZDs) increase the potency of GABA through modulatory interactions, thereby enhancing GABA-in- ) and bound radioactivity was determined by filtration. Nonspecific binding, determined in the presence of 1 mM flurazepam, has been subtracted. Line shows computer-generated 1 -site fit to the data. Inset, Same data plotted by the method of Scatchard. The parameters obtained were K,, = 1.1 nM; &n,x = 9 17 fmol/mg protein.
buffered salt solution (PBSS: 123 mM NaCl, 5.4 mM KCl, 11 mM NaPO,, 0.9 mM CaCl,, 0.4 mM MgSO,, 22.2 mM glucose, pH 7.4). Tissue was transferred to lo-20 volumes of 0.32 M sucrose and homogenized in a close-fittingglass/Teflon homogenizer (10 strokes). The homogenate was centrifuged at 1000 x g for 5 min, and the supematant was then centrifuged at 30,000 x g for 20 min. The resulting pellet (P,) was homogenized in PBSS and frozen at -70°C. Tissue was later thawed, washed twice by centrifugation in PBSS, and refrozen. For GABAenhancement studies, tissue was washed twice in PBSS and then twice in ice-cold water, followed by 2 more washes in PBSS, tissue was then refrozen. Binding assays. Immediately before use in binding assays, tissue was thawed and suspended in the appropriate volume of ice-cold PBSS. Assay tubes containing 3H-flunitrazepam or 'H-RoS-4864 (and other drugs as required) in PBSS were chilled on ice, and incubations were started by the addition of P, membranes; total incubation volume was 0.5 ml. For saturation experiments, the concentration of radioligand was varied. For competition experiments, assay tubes contained 1 concentration of 3H-flunitrazepam (generally 2 or 5 nM) or 3H-Ro5-4864 (generally 1 or 2 nM) and various concentrations of unlabeled drug. Nonspecific binding was determined in the presence of 1 mM flurazepam (for 'H-flunitrazepam binding) or 2 mM flurazepam (for 'H-Ro5-4864 binding) and was subtracted from total binding (no competitor) to yield specific binding; similar values for nonspecific binding were obtained with other BZD competitors. All determinations were performed in at least triplicate. Incubations were continued on ice until equilibrium was reached (60 min for 3H-flunitrazepam, 90 min for 3H-Ro5-4864) and terminated by the addition of 5 ml ice-cold PBSS. Incubation mixtures were immediately poured over Whatman GF/B glass fiber filters, filtered rapidly under vacuum, and washed 3 times with ice-cold PBSS (5 ml each). Filters were placed in scintillation vials, 5 ml Liquiscint was added, and radioactivity was determined by liquid scintillation counting in a Packard Tricarb counter, model 4530 (counting efficiency, ca. 4 1%).
Photoajinity labeling. "Photoinactivation" of P, homogenates was carried out as described previously . Membrane homogenates (0.1-5 mg protein/ml) were incubated with 100 nM flunitrazepam (20 min, 4°C) then irradiated 20 min at a distance of l-2 cm with a General Electric F40BLB blacklight bulb. Solution depth was less than 5 mm to minimize attenuation of ultraviolet light. Control membranes were treated identically except that they were not irradiated. Membranes were washed 4 times by centrifugation (30,000 x g, 20 min) and resuspension in 40-50 ml PBSS, and then frozen at -70°C.
Photolabeling of P, membranes was performed using a protocol identical to that for photoinactivation except that 5 nM 3H-flunitrazepam was employed. Some incubations contained 1 mM flurazepam to define nonspecific photolabeling. SDS gel electrophoresis. SDS-PAGE was performed according to the method of Laemmli (1970) . Samples were boiled 3 min in buffer containing 0.625 M Tris-HCl (pH 6.8) 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, and 0.00 1% bromophenol blue (tracking dye) before application to 10% polyactylamide gels. The following proteins were used as molecular-weight (Mi) standards: phosphorylase-B (M, = 92,000) BSA (M. = 66.200). ovalbumin (A4. = 45.000). carbonic anhvdrase IM. = 3 1 ,OdO); soybean tipsin inhibitor (M, = 21;500), and lysozyme (i, = 14,400). Electrophoresis was at 20 mA for 6-8 hr. Following electrophoresis, gels were fixed and stained with 0.4% Coomassie Brilliant blue solution in 50% methanol/7% acetic acid and destained in 7% acetic acid. Lanes were cut into 1 mm segments, the slices were dissolved overnight in 0.5 ml hydrogen peroxide, and radioactivity was determined by scintillation counting.
Stock solutions. Chlordiazepoxide and flurazepam were made up in water or directly in PBSS. Other BZDs were dissolved in DMSO and then diluted into PBSS; the final concentration of dimethylsulfoxide (DMSO) was generally 0.05-0.5% and never exceeded 1%. The concentration of solvent was kept constant within any experiment and control experiments demonstrated that DMSO in this concentration range affected specific binding by less than 5%.
Control experiments suggested that RoS-4864 precipitated from aqueous stock solutions. Ro5-4864 was dissolved in isopropanol, and the optical density was measured at 230 or 3 15 nM in a Bausch & Lomb Spectronic 7 10 spectrophotometer using quartz cuvettes. The concentration of Ro5-4864 was calculated from the equation C = A/EL, where C is concentration; A, absorbance; E, extinction coefficient (34,100 and 2390 at 230 and 315 nm, respectively, both in isopropanol); and L, 1 cm path length (extinction coefficients kindly provided by Dr. V. Toome, Hoffman-La Roche, Nutley, NJ). For binding studies, dilutions were made up from a stock solution (1.23 mM) , and the concentration of isopropanol was kept constant in all assay tubes (0.5%).
Data analysis. Data were analyzed by an Apple computer using a nonlinear regression program based on the "patternsearch" algorithm of Hooke and Jeeves (196 1) . Data were weighted according to the inverse of the variance from replicate determinations. Data were fitted to theoretical 1-and 2-site models, and the adjusted sums-of-squares were compared. The adjusted sum-of-squares was calculated from the equation S,, = Sl(n -p), where n is the number of experimental values and p is the number of adjustable parameters (3 for the l-site model, 5 for the 2-site model). For 2-site models, the binding to each site is reported as a percentage of the total binding. K, values were calculated from the equation K, = I&/(1 + L*/K,*) (Cheng and Prusoff, 1973) , where IC,, is the concentration of competitor that inhibits 50% of the binding of radioligand, L* is the concentration of radioligand, and K,* is the dissociation constant of the radioligand. Figure  1 . As the concentration of 3H-flunitrazepam was increased, nonspecific binding increased linearly, whereas specific binding saturated at higher concentrations. Scatchard analysis ( Fig. 1 , inset) yields a straight line consistent with binding to a single highaffinity site. The K, value obtained was 2.3 f 0.1 nM, and the receptor density (II,,,,,) was 1.27 f 0.18 pmol/mg protein (n = 5 experiments). The K,'s for a series of BZDs were determined by competition experiments employing 20 d P, membranes. Membrane aliquots were incubated with 3H-flunitrazepam and various concentrations of unlabeled drug until equilibrium was reached. Figure 2 shows the results of a representative experiment in which flunitrazepam was used as competitor. As the concentration of flunitrazepam was increased, a progressive decrease of bound radioactivity was observed. The shape of the curve was consistent with binding to a single site. The K, value was 2.6 f 0.5 nM (n = 5), similar to the value of 2.3 f 0.1 obtained from saturation binding. Table 1 shows the K, values for a number of BZDs as determined from competition experiments similar to that shown in Figure 2 . Equilibrium binding was also measured at 37°C. The K, for flurazepam (2 10 nM, mean of 2 experiments) was decreased approximately 5-fold as compared to values obtained at O"C, in general agreement with results obtained with rat brain homogenates (Speth et al., 1979) .
Equilibrium binding to membranes from 7 d embryonic brain Competition experiments performed with 7 d membranes resulted in flattened or nonsigmoidal displacement curves. A representative experiment in which flurazepam was used as competitor is shown in Figure 3 . Hill analysis yielded a straight line with a slope of 0.6, inconsistent with Michaelis-Menten binding to a single site. When analyzed by nonlinear regression, the displacement data were well described by a 2-site model in which about 70% of the specific binding was to a high-affinity site (site-A, K, = 40 nM for flurazepam) and 30% was to a loweraffinity site (site-B, K, = 20 PM). The small size of 5 d embryonic brain precluded detailed experiments, but the results were similar to those obtained with 7 d brain membranes, consistent with the presence of multiple binding sites.
As 3H-flunitrazepam was the radioligand employed in these studies, it was important to determine if flunitrazepam bound with different affinities to the 2 sites. Competition experiments using unlabeled flunitrazepam indicated that flunitrazepam binds with high and low affinity to site-A and site-B, respectively. Clonazepam, flunitrazepam, diazepam, flurazepam, and chlordiazepoxide bound to 7 d membranes with both high and low affinities (Table 1) , and the ratio of high-to low-affinity binding was similar for the different ligands. The results from all experiments on these 5 BZDs suggest that at 5 nM )H-flunitrazepam, 21.7 ? 2.9% (n = 12) of the specific binding was to a distinct class of low-affinity sites. The B,,, for site-A, extrapolated from competition curves, was 0.3 16 rt 0.06 pmol/mg protein (n = 6). The ability to detect site-B with 3H-flunitrazepam, despite its low affinity, suggested that the site must be present in great abundance relative to site-A; the number of low-affinity sites present in embryonic brain will be discussed below (see section on binding of 3H-Ro5-4864). Binding to 7 d membranes was also measured at 37°C. Binding to site-B was detectable at this temperature, although the affinity of flunitrazepam (determined from competition experiments) was about 4-fold lower than at 0°C. High-affinity BZD binding to rat brain homogenates is modulated by chloride ions (Costa et al., 1979) . As our standard buffer (PBSS) contains 0.4 mM Cl-, competition binding experiments (using unlabeled flurazepam) were also conducted in chloride-free Tris-acetate buffer (50 mM, pH 7.4). The affinities and proportions of site-A and site-B were similar to those obtained with PBSS.
Kinetics of 3H-jlunitrazepam binding to 7 d membranes
In the experiments described above, bound radioactivity was separated from free by a filtration assay in which the wash time was 10 sec. To determine how much bound radioactivity was lost during washing, membranes were incubated with 58 nM 3H-flunitrazepam and 1 PM unlabeled flunitrazepam. Under these conditions >90% of the specific binding of 3H-flunitrazepam was to site-B. Incubation was continued for 45 min, sufficient for attainment of equilibrium, then 1 mM flurazepam (final con- centration) was added. After various times, samples were poured over filters and washed as described in Materials and Methods. Dissociation of 3H-flunitrazepam from site-B was slow and firstorder (Fig. 4, bottom) , exhibiting a half-time of about 2 min and a k,,, of 0.33 min-I. k,, (= k,,,JK,) is thus equal to 2.05 x lo5 M-I min-I, assuming a simple bimolecular reaction mechanism, yielding a half-time for association of ca. 2 min at 5 nM flunitrazepam. This is consistent with the observation that binding of 5 nM 3H-flunitrazepam reached equilibrium after about 20 min (Fig. 4, bottom) .
Characterization of high-and low-ajinity binding sites For further characterization ofthe embryonic BZD binding sites, the stereospecificity of high-and low-affinity binding sites and their sensitivity to heat and proteolytic enzymes were examined. The stereospecificity of binding to both site-A and site-B was ample, at 60 FM, B 10( +) displaced 100 f 5% of specific binding, whereas BlO(-) displaced only 49 f 5%.
High-affinity binding was eliminated when membranes were heated (lOo"C, 90 min). Although low-affinity binding was still detected after heating, the binding no longer displayed the stereospecificity observed with control membranes. For example, following heating, 60 PM BlO(+) and B lo(-) displaced 74 f 11 and 76 * 11% of specific binding, respectively. Additionally, binding to site-A and to site-B was decreased approximately 75% by trypsin (Table 2) . Thus, both the high-and low-affinity binding sites displayed the stereospecificity and heat-and protease-sensitivity expected of functional BZD receptors.
To determine if GABA enhances BZD binding to embryonic chick brain, membranes were washed extensively to remove endogenous GABA (see Materials and Methods), and then the binding of 3H-flunitrazepam was measured in the absence and presence of added GABA. Table 3 shows that GABA increased specific binding 58% over control values in 7 d membranes, and this effect was blocked by the GABA-receptor antagonist bicuculline (100 WM); similar results were obtained in 20 d brain membranes. "Central" versus "peripheral" sites In addition to the binding sites present in the brain, high-affinity BZD binding sites have also been observed in various peripheral (i.e., non-neural) tissues such as kidney (Braestrup and Squires, 1977; Regan et al., 1981) . The brain type, or "central," and kidney type, or "peripheral," binding sites can be distinguished pharmacologically: the central site displays high affinity for flurazepam and clonazepam but low affinity for Ro5-4864 (a convulsant BZD), whereas the reverse relationship is observed for the peripheral site. Interestingly, BZD binding sites with high affinity for Ro5-4864 have also been observed in cell cultures of both neural (Syapin and Skolnick, 1979; Walker and Peacock, 1981; Sher, 1985) and non-neural (Matthew et al., 1981; Beaumont et al., 1984; Wang et al., 1984) In 7 d brain membranes, however, Ro5-4864 displaced with high affinity (K, = 40 nM, n = 2) ahout 30% of the specifically bound 3H-flunitrazepam (Fig. 5) . Flurazepam displaced about 30% of the specific binding with low affinity (Fig. 3) . These 4864 could be used to characterize this site. Figure 6 shows that the binding of 3H-Ro5-4864 to 7 d membranes was saturable and of high affinity (K, = 41 nM). Interestingly, the number of binding sites was found to be similar in both early and late embryonic brain (B,,, = 2.7 and 2.5 pmol/mg protein in 7 and 20 d brain membranes, respectively).
To test the hypothesis that the 3H-Ro5-4864 binding site in embryonic chick brain corresponds to site-B (as determined by low-affinity binding of 3H-flunitrazepam), we tested various BZDs for their ability to compete for specific 3H-Ro5-4864 binding in 7 d brain. Figure 7 shows a representative experiment in which flurazepam was used as competitor.
Flurazepam inhibited all of the specific binding with low affinity (K, ca. 27
PM;
see Table l ), similar to the inhibition of the low-affinity component of 3H-flunitrazepam binding (Table 1 , Fig. 3 ). Comparable results were obtained with all BZDs tested ( Table 1 ).
The close agreement between K, values for inhibition of 3H-Ro5-4864 binding and inhibition of 3H-flunitrazepam binding to site-B supports the contention that these 2 sites are identical.
As with the binding of 3H-flunitrazepam to site-B, 3H-Ro5-4864 binding displays a number of characteristics expected of a functional receptor. As shown in Figure 8 , B 10( +) (K, = 0.36 + 0.11 WM, y2 = 3) was a more potent inhibitor of 3H-Ro5-4864 binding than BlO(-) (K, = 8.7 * 1.1 FM). When membranes were heated (lOoOC, 90 min), specific binding was reduced to 35% of control; binding was also sensitive to protease treatment (Table 2 ).
Photoafinity labeling of embryonic BZD binding sites
To determine if a BZD receptor in embryonic brain homogenates could be photoaffinity-labeled by exposure to ultraviolet light in the presence of flunitrazepam, 20 d brain membranes were photolabeled with 3H-flunitrazepam and then subjected to SDS-PAGE. Radioactivity migrated as bands of M, 48,000 and 5 1,000 (Fig. 9) , in good agreement with results obtained with adult rat brain (Battersby et al., 1979; Sieghart and Karobath, 1980; Thomas and Tallman, 198 1) . When 7 d membranes were photolabeled, a pattern similar to that obtained with 20 d membranes was observed (Fig. 9) .
To determine if site-B could be photoaffinity-labeled, 7 d et al. -Benzodi azepi ne Receptor Development membranes were photoinactivated and clonazepam was tested for its ability to compete for 3H-flunitrazepam binding. The data in Figure 10 demonstrate that photoinactivation markedly reduced binding to site-A, whereas binding to site-B was unaffected, indicating that the latter is resistant to photoaffinity labeling. Thus, both labeled bands observed on SDS gels are associated with site-A.
Developmental regulation of BZD binding sites Site-A increases in number approximately S-fold between embryonic days 7 and 20 (see above). To better describe this change, we further examined 3H-flunitrazepam binding to brain membranes derived from 10, 12, and 15 d embryos. As shown in Figure 11 (see legend for methods), the increase in the levels of site-A occurred gradually during embryonic development. Interestingly, during this same period, the number of site-B sites as determined by 3H-Ro5-4864 binding remained constant.
Discussion
We previously identified 2 classes of BZD binding sites in the embryonic chick brain (Chan et al., 1983) . In the present communication we characterize these sites further and describe their development during embryogenesis. High-affinity 3H-flunitrazepam binding sites (site-A) are present in the embryonic chick brain as early as embryonic day 5 (Hamburger and Hamilton stage 27) and increase approximately 5-fold by embryonic day 20 (1 d prehatch) . Because of the small size of the embryonic brain, we focused our studies on embryos that had developed for 7 d or more. A number of observations indicate that site-A is part of a functional BZD-GABA receptor complex. First, binding to site-A is potentiated by GABA (Table 3) . Second, the relative affinities of a number of BZDs for binding to site-A correlate well with their relative potencies for potentiating GABA chemosensitivity in embryonic chick spinal cord cell cultures (Chan et al., 1983) . Last, potentiation of GABA responses is inhibited by photoinactivation (Chan et al., 1983; Borden et al., 1984) as is binding to site-A (Fig. 10) .
When 7 or 20 d embryonic brain membranes are photoaffinity-labeled with 3H-flunitrazepam and analyzed by SDS-PAGE, radioactivity is observed in 2 bands of apparent molecular weight 48,000 and 5 1,000 Da. The apparent resistance of site-B to photoinactivation (Fig. 10) argues that both labeled bands correspond to site-A. The similar pattern obtained at early and late developmental stages indicates that neither the molecular weights nor relative amounts of these receptor subunit proteins change appreciably during embryogenesis. It will be interesting to determine if the photolabeling pattern changes postnatally, as has been observed in the rat (Sieghart and Mayer, 1982; Eichinger and Sieghart, 1986) .
Interestingly, GABA enhanced 3H-flunitrazepam binding at all stages examined, indicating that site-A and GABA receptors are coupled early in development (by day 7). The enhancement by GABA of BZD binding is a good indicator of the ability of BZDs to potentiate GABA-induced conductance increases . Thus, it seems likely that functional BZD receptors are already present at the time when cell cultures are prepared from the embryonic chick CNS (Chan et al., 1983; Borden et al., 1984) . This finding is consistent with the ability of GABA and BZDs to inhibit the spontaneous motility of 4 d embryos (Reitzel et al., 1979; Maderdrut et al., 1983) , and also with biochemical studies suggesting that binding sites for BZDs and those for GABA reside on the same protein (Sigel and Barnard, 1984; Schoch et al., 1985) . The precocious development of a functional BZD receptor suggests that modulation of neural activity may be important during early development of the chick CNS. It is interesting that BZD binding sites in the rat brain are first detected on gestational day 14 (Schlumpf et al., 1983 ). This dramatic difference in the rate of development of the BZD-GABA receptor complex may be another example of rapid embryonic maturation in avians compared with fetal development in mammals; alternatively, it may represent a fundamental difference in the functional role of neuromodulation in avian and mammalian development.
In contrast to the results obtained with 20 d membranes, competition curves employing membranes from younger embryos were "flattened," inconsistent with Michaelis-Menten binding to a single site. The results suggest the existence of a high-affinity component (site-A) and a second site of considerably lower affinity (site-B). The identification of low-affinity binding is dependent on the use of a high concentration of competitor to define nonspecific binding. In this investigation, 1 mM flurazepam was employed because of its high affinity and its high solubility in aqueous buffers. Importantly, despite its low affinity, 3H-flunitrazepam dissociates slowly (t, = 2 min) from site-B. Thus, little bound radioactivity is lost during the filtration and washing procedure (total time, ca. 10 set).
Site-B displays characteristics expected of a receptor binding site, including stereospecific binding and sensitivity to inactivation by heat and trypsin. Interestingly, Ro5-4864 was found to bind with high affinity to site-B (K, ca. 40 nM). This finding prompted us to examine the binding of 3H-Ro5-4864 to embryonic brain membranes. The K, values for inhibition of 3H- The high affinity of Ro5-4864 for site-B clearly distinguishes this site from site-A and suggests a similarity between site-B and the "peripheral" site previously identified in non-neural tissues (such as kidney) and, more recently, in mammalian brain. However, site-B and the peripheral site may be different: there is only a fair correlation between the affinities of a series of BZDs for binding to the 2 sites (Y = 0.86; see Table 1 ). A further distinction is that binding to site-B displays stereospecificity (Fig. 8) a property not shared by the peripheral site (Schoemaker et al., 1983) . It is not known if site-B is the chick equivalent of the peripheral site or if it represents a distinct receptor.
The function(s) of high-affinity 3H-Ro5-4864 binding sites, such as site-B and the peripheral site, remains to be elucidated. Peripheral binding sites have been identified in the brains of a number of mammalian species, but it is not clear whether such sites mediate the behavioral effects of Ro5-4864 (for review, see Pellow and File, 1984) . Interestingly, the levels and distribution of peripheral binding sites vary considerably among species. For example, the rat brain contains relatively few peripheral sites (205 fmol/mg protein: Schoemaker et al., 1983) , and these appear to be restricted to the ependyma and choroid plexus (Anholt et al., 1985) ; in contrast, the cat contains high levels ofperipheral sites (ca. 6 pmol/mg protein), and these are widely distributed throughout the brain (Benavides et al., 1984) . High receptor numbers are also found in the guinea pig brain (Weissman et al., 1984) . The significance of these results is not understood but they should be considered when interpreting behavioral studies.
The number of peripheral sites in the neonatal rat brain is the same as in the adult (Anholt et al., 1985) , whereas GABAlinked high-affinity 3H-flunitrazepam binding sites increase approximately lo-fold between these stages (Regan et al., 1980) . The present study demonstrates that the levels of site-B in the chick brain are stable by embryonic day 7, whereas site-A increases throughout embryonic development. These results indicate a further similarity between site-B and the peripheral site and suggest that 3H-Ro5-4864 binding sites may be important during early stages of development.
The BZDs produce diverse effects in a number of non-neural tissues, and these effects do not appear to be mediated by GABAlinked, high-affinity BZD receptors. It has been suggested that peripheral sites mediate the ability of BZDs to inhibit the proliferation of thymoma cells (Wang et al., 1984) and to induce melanogenesis in melanoma cells (Matthew et al., 1981) . In contrast, peripheral binding sites do not appear to mediate BZDinduced differentiation of erythroleukemia cells (Wang et al., 1984) . Similarly, there is a poor correlation between the peripheral binding site and the potencies of various BZDs for inducing omithine decarboxylase activity and inhibiting NGFmediated neurite outgrowth in PC 12 cells (Morgan et al., 1985) . Other actions of the BZDs-such as inhibition of protein turnover in skeletal muscle cell cultures (Bandman et al., 1978) , alteration of skeletal muscle contractility (Khan and Edman, 1983) , and inhibition of cell motility in fibroblast cultures (Nagele et al., 1983)-require micromolar concentrations of diazepam, consistent with an involvement of site-B or another lowaffinity site. The function of site-B remains an interesting question. It will be of interest to determine whether site-B modulates the migration and/or proliferation of neurons and glial cells in the embryonic CNS.
In conclusion, we have demonstrated that 2 types of BZD binding sites are present in the developing chick CNS and that both appear early in embryogenesis.
High-affinity 3H-flunitrazepam binding sites (site-A) are coupled to GABA receptors by embryonic day 7, and the number of sites per milligram of protein increases 5-fold between embryonic days 7 and 20. Site-B, which displays high affinity for 3H-Ro5-4864, differs from any previously identified binding site. The number of site-B sites in embryonic day 7 brain exceeds the number of site-A by 8.6-fold, and the levels of site-B do not change between 7 and 20 d ofembryonic development.
The function of site-B is unknown, but its predominance in young embryos (relative to site-A) suggests that it may play a role in the early embryonic CNS.
